Key result
Among 1,231 patients in the Foshan area, the frequencies of rapid, intermediate, and slow CYP2C19 metabolizer genotypes were 41.51%, 44.76%, and 13.73%, respectively.
Why the study?
Data on CYP2C19 genotypes and allele distribution patterns in the Chinese population of the Foshan area were scarce.
Cross-Sectional (n=1,231)
The study establishes the baseline CYP2C19 allele frequencies in the Foshan population, highlighting a high prevalence of intermediate and slow metabolizers (over 58%) which may impact clopidogrel efficacy.
High intermediate/slow CYP2C19 prevalence may blunt clopidogrel response; hypothesis-generating for local genotyping studies.
Background: The CYP2C19 gene is highly polymorphic, and CYP2C19 is involved in the broad interindividual variability of the clinical efficacy of certain clinical medications, such as clopidogrel. However, data on the CYP2C19 genotype in the Chinese population of the Foshan area of Guangdong Province are scarce. The purpose of this study was to determine CYP2C19 genetic polymorphisms in patients in the Foshan area and to compare the CYP2C19 genotype frequencies in different populations to determine the allele distribution pattern to identify the most appropriate prescription.Methods: The CYP2C19 gene was detected in 1231 patients on a gene chip platform, and the genotype frequencies of CYP2C19 in Foshan populations from different populations were compared.Results: The frequencies of CYP2C19*1, *2 and *3 in the Foshan population were 63.89%, 30.46% and 5.65%, respectively. For the three metabolic types, the frequency associated with the rapid metabolism type (*1/*1) was 41.51 [95% confidence interval (CI) 40.11 to 42.91%]; that for the intermediate metabolism type (*1/*2, *1/*3) was 44.76% (95% CI 43.34 to 46.18) and that for the slow metabolism type (*2/*2, *2/*3, *3/*3) was 13.73% (95% CI 12.75 to 14.71%). In the Foshan population, the frequencies of the CYP2C19 *2 and *3 alleles were similar to those previously reported for Chinese and other Asian populations.Conclusion: Our study is a report on the genetic basis of CYP2C19 polymorphism in the Foshan population. Our results will potentially contribute to the improvement of pharmacotherapy effectiveness by providing personalized medicine for the Foshan population.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2022) conducted a cross-sectional in CYP2C19 genetic polymorphisms (n=1,231). CYP2C19 genotype was evaluated on CYP2C19 genotype frequencies. Among 1,231 patients in the Foshan area, the frequencies of rapid, intermediate, and slow CYP2C19 metabolizer genotypes were 41.51%, 44.76%, and 13.73%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: